Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection

Real-world results of nivolumab monotherapy against HCC are lacking in the hepatitis B virus (HBV)-endemic, Asia-Pacific regions. Moreover, heterogeneous responses to immune checkpoint inhibitors have rarely been described in advanced HCC. The aim of this study is to evaluate the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Pil Soo, Jang, Jeong Won, Lee, Jaejun, Lee, Soon Kyu, Lee, Hae Lim, Yang, Hyun, Nam, Hee Chul, Lee, Sung Won, Bae, Si Hyun, Choi, Jong Young, Han, Nam Ik, Yoon, Seung Kew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338665/
https://www.ncbi.nlm.nih.gov/pubmed/32695681
http://dx.doi.org/10.3389/fonc.2020.01043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338665/
https://www.ncbi.nlm.nih.gov/pubmed/32695681
http://dx.doi.org/10.3389/fonc.2020.01043

Ejemplares similares